Telpegfilgrastim injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Xiamen Amoytop Biotech Co., Ltd.
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- To reduce infection presenting as febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer treatment likely to cause febrile neutropenia. Not for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
- Indication source and scope
- 2025-03-03
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to patients who experienced severe neutropenia during previous chemotherapy.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.nmpa.gov.cn/directory/web/nmpa/images/1707039824076019627.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://rrrorwxhjokolk5p-static.micyjz.com/%E7%8F%AE%E9%87%91%E8%AF%B4%E6%98%8E%E4%B9%A6-aidloBpkKnillSRolompklpjp.pdf
Open the interactive record, public price references and discussions